Research programme: antifungals - GPC Biotech
Alternative Names: Cak1 inhibitors - GPC Biotech; GGTase inhibitors - GPC BiotechLatest Information Update: 05 May 2003
At a glance
- Originator GPC Biotech Inc
- Class Small molecules
- Mechanism of Action CDC2 protein kinase inhibitors; Geranylgeranyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 05 May 2003 This antifungal research programme is available for licensing (http://www.gpc-biotech.com)
- 11 May 2000 Preclinical development for Mycoses in USA (Unknown route)